<?xml version='1.0' encoding='utf-8'?>
<document id="22594507"><sentence text="A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele."><entity charOffset="58-69" id="DDI-PubMed.22594507.s1.e0" text="simvastatin" /></sentence><sentence text="Simvastatin interacts with warfarin, but the strength of the interaction varies between individual patients, indicating a genetic predisposition"><entity charOffset="0-11" id="DDI-PubMed.22594507.s2.e0" text="Simvastatin" /></sentence><sentence text="" /><sentence text="The influence of the CYP2C9*2 and CYP2C9*3 polymorphisms on the interaction between simvastatin and warfarin was analyzed in data from 1132 patients"><entity charOffset="84-95" id="DDI-PubMed.22594507.s4.e0" text="simvastatin" /><entity charOffset="100-108" id="DDI-PubMed.22594507.s4.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.22594507.s4.e0" e2="DDI-PubMed.22594507.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22594507.s4.e0" e2="DDI-PubMed.22594507.s4.e1" /></sentence><sentence text="" /><sentence text="Simvastatin use reduced warfarin dose requirements by 29% in carriers of the CYP2C9*3 allele, compared with 5% in noncarriers"><entity charOffset="0-11" id="DDI-PubMed.22594507.s6.e0" text="Simvastatin" /></sentence><sentence text=" A regression model showed a significant influence of CYP2C9*3 on the drug-drug interaction, predicting a warfarin dose reduction of 25% in CYP2C9*3 heterozygotes and 43% in CYP2C9*3 homozygotes"><entity charOffset="54-62" id="DDI-PubMed.22594507.s7.e0" text="CYP2C9*3" /></sentence><sentence text="" /><sentence text="Our data indicate that the CYP2C9*3 polymorphism predisposes for a pharmacologic interaction between warfarin and simvastatin"><entity charOffset="114-125" id="DDI-PubMed.22594507.s9.e0" text="simvastatin" /></sentence><sentence text="" /></document>